E-ISSN 2149-388X | ISSN 2149-0430
 

Case Report 


A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?

Habibullah Aktas, Serkan Oner, Zulal Oner.

Abstract
Background: Scleredema diabeticorum is a dermatosis characterized by hardening of skin over the upper back. It is commonly seen in poor-controlled diabetic patients. Therapeutic options are limited. Psoralen and ultraviolet A therapy (PUVA), methotrexate, and topical steroids have been used with some success. Pentoxifylline is a xanthine derivative used mainly in peripheral vascular diseases. It also has antifibrotic effects due to its collagen synthesis inhibition action.
Case Presentation: In this paper, a trial of intralesional pentoxifylline treatment and magnetic resonance images of a male patient with scleredema diabeticorum are presented. Some subjective symptoms of the patient improved after this treatment, but, the thickness of the lesion did not change.
Conclusion: Pentoxifylline, probably via the oral route, could still be thought in such patients unresponsive to conventional approaches due to its antifibrotic activity and high safety profile.

Key words: Scleredema, Pentoxifylline, MRI


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Habibullah Aktas
Articles by Serkan Oner
Articles by Zulal Oner
on Google
on Google Scholar
Article Statistics
 Viewed: 374
Downloaded: 48
Cited: 0


How to Cite this Article
Pubmed Style

Aktas H, Oner S, Oner Z. A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. Ulutas Med J. 2019; 5(3): 225-228. doi:10.5455/umj.20190616024428


Web Style

Aktas H, Oner S, Oner Z. A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. https://www.ulutasmedicaljournal.com/?mno=53006 [Access: September 17, 2019]. doi:10.5455/umj.20190616024428


AMA (American Medical Association) Style

Aktas H, Oner S, Oner Z. A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. Ulutas Med J. 2019; 5(3): 225-228. doi:10.5455/umj.20190616024428



Vancouver/ICMJE Style

Aktas H, Oner S, Oner Z. A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. Ulutas Med J. (2019), [cited September 17, 2019]; 5(3): 225-228. doi:10.5455/umj.20190616024428



Harvard Style

Aktas, H., Oner, . S. & Oner, . Z. (2019) A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. Ulutas Med J, 5 (3), 225-228. doi:10.5455/umj.20190616024428



Turabian Style

Aktas, Habibullah, Serkan Oner, and Zulal Oner. 2019. A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. THE ULUTAS MEDICAL JOURNAL, 5 (3), 225-228. doi:10.5455/umj.20190616024428



Chicago Style

Aktas, Habibullah, Serkan Oner, and Zulal Oner. "A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?." THE ULUTAS MEDICAL JOURNAL 5 (2019), 225-228. doi:10.5455/umj.20190616024428



MLA (The Modern Language Association) Style

Aktas, Habibullah, Serkan Oner, and Zulal Oner. "A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?." THE ULUTAS MEDICAL JOURNAL 5.3 (2019), 225-228. Print. doi:10.5455/umj.20190616024428



APA (American Psychological Association) Style

Aktas, H., Oner, . S. & Oner, . Z. (2019) A Case of Scleredema Diabeticorum: Could Pentoxifylline Be a Therapeutic Option?. THE ULUTAS MEDICAL JOURNAL, 5 (3), 225-228. doi:10.5455/umj.20190616024428